miRNA Detection Methods and Clinical Implications in Lung Cancer

Usó, Marta; Jantus‐Lewintre, Eloísa; Sirera, Rafael; Bremnes, Roy M.; Camps, Carlos

doi:10.2217/fon.14.93

Cited by 34 publications

(13 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGS technology allows the whole microRNAome of each sample to be analyzed with high sensitivity, a wide dynamic range, high accuracy, and extraordinary technical reproducibility [ 24 , 25 ]. In the cancer research context, NGS technology is especially useful compared to other methodologies because it allows the detection of miRNAs not yet described [ 24 , 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundThe average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value.MethodsSequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = 32). We validated 22 randomly selected differentially-expressed miRNAs by quantitative real time PCR in tumor and adjacent normal tissue samples (N = 178). Kaplan-Meier survival analysis and Cox regression were used in multivariate analysis to identify independent prognostic biomarkers.ResultsNGS analysis revealed that 39 miRNAs were dysregulated in NSCLC: 28 were upregulated and 11 were downregulated. Twenty-two miRNAs were validated in an independent cohort. Interestingly, the group of patients with high expression of both miRNAs (miR-21high and miR-188high) showed shorter relapse-free survival (RFS) and overall survival (OS) times. Multivariate analysis confirmed that this combined signature is an independent prognostic marker for RFS and OS (p = 0.001 and p < 0.0001, respectively).ConclusionsNGS technology can specifically identify dysregulated miRNA profiles in resectable NSCLC samples. MiR-21 or miR-188 overexpression correlated with a negative prognosis, and their combined signature may represent a new independent prognostic biomarker for RFS and OS.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several miRNAs have been well characterized in human diseases including lung cancer and bladder cancer (52,53). However, only a few lncRNAs have been mechanically and functionally characterized.…”

Section: Discussionmentioning

confidence: 99%

Prognostic signatures for renal cancer as identified by long non-coding and miRNA competing endogenous network analysis.

et al. 2018

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) make up a significant portion of transcripts that are not translated into proteins and lncRNAs were previously thought to be transcriptional noise. Recently, there has been increased interest in lncRNAs due to their diverse functions in human cancers. At present, lncRNAs are considered to be the main component of the competing endogenous RNA (ceRNA) network due to their regulatory role in protein-coding gene expression by acting as microRNA (miRNA) sponges. However, the function of the lncRNA-mediated ceRNA network in renal cell carcinoma remains unknown. To examine the specific mechanism, we compared the expression profiles of mRNAs, lncRNAs, and miRNAs between renal cell carcinoma tissues and non-tumor normal tissues using the Gene Expression Omnibus database. As a result, 5 lncRNAs were identified as aberrantly expressed and significantly correlated with the tumorigenesis and/or progression of renal cell carcinoma with the threshold value of absolute log2 fold change >1 and corrected P<0.05. Among the 5 dysregulated lncRNAs, 2 of them were prognostic biomarkers according to the overall survival analysis for patients with renal cell carcinoma. We successfully constructed a dysregulated lncRNA-associated ceRNA network, which included 4 renal cell carcinoma‑specific lncRNAs, 17 mRNAs and 2 miRNAs. In summary, the present study identified new lncRNA biomarkers and potential targets for renal cell carcinoma therapy. In particular, the novel ceRNA network identified in our study will be vital for understanding the regulatory mechanisms mediated by lncRNAs in the pathogenesis of renal cell carcinoma.

show abstract

“…They found that CTC detection was associated with the cancer stage. The few studies on circulating miRNA in MCC used RT-qPCR as detection technology [142,150], like for other cancers [151,152]. The MCC miRNome has been investigated mostly in formalin-fixed paraffin-embedded tumor samples [153,154], and the miRNAs identified as MCC-specific could now be evaluated in liquid biopsies.…”

Section: Ctcs and Circulating Mirnasmentioning

confidence: 99%

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

Boyer¹,

Cayrefourcq²,

Dereure

et al. 2020

Cancers

View full text Add to dashboard Cite

Melanoma and Merkel cell carcinoma are two aggressive skin malignancies with high disease-related mortality and increasing incidence rates. Currently, invasive tumor tissue biopsy is the gold standard for their diagnosis, and no reliable easily accessible biomarker is available to monitor patients with melanoma or Merkel cell carcinoma during the disease course. In these last years, liquid biopsy has emerged as a candidate approach to overcome this limit and to identify biomarkers for early cancer diagnosis, prognosis, therapeutic response prediction, and patient follow-up. Liquid biopsy is a blood-based non-invasive procedure that allows the sequential analysis of circulating tumor cells, circulating cell-free and tumor DNA, and extracellular vesicles. These innovative biosources show similar features as the primary tumor from where they originated and represent an alternative to invasive solid tumor biopsy. In this review, the biology and technical challenges linked to the detection and analysis of the different circulating candidate biomarkers for melanoma and Merkel cell carcinoma are discussed as well as their clinical relevance.

show abstract

miRNA Detection Methods and Clinical Implications in Lung Cancer

Abstract: Future MedicineUsó, M.; Jantus Lewintre, E.; Sirera Pérez, R.; Bremnes, RM.; Camps, C. (2014)

Cited by 34 publications

References 82 publications

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

Prognostic signatures for renal cancer as identified by long non-coding and miRNA competing endogenous network analysis.

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

Contact Info

Product

Resources

About